Latest Breaking News On - Langone vaccine - Page 1 : comparemela.com

Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 DURHAM, N.C., Jan. 25, 2021 Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic. The study, CoVPN 3501, was conducted in collaboration with Eli Lilly and Company in skilled nursing facilities (SNFs) across the United States. Residents and staff at SNFs participated in the trial.    A total of 1,097 participants (340 residents, 757 staff) were randomized to receive either a single 4,200 mg dose of LY-CoV555 or placebo (saline). Half of the study participants received LY-CoV555 and h

New yorkUnited statesNew york universityMarkj mulliganMyron cohenEli lillyKevin bokochRichard novakNational institute of allergyUniversity of north carolinaPrevention trials networkUs national institute of allergyPrevention networkPrevention network coYork universityVaccine trials network